Skip to Main content Skip to Navigation
Journal articles

Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

Abstract : The mechanism of action of empagliflozin in reducing the risk of adverse cardiovascular outcomes vs placebo in patients with type 2 diabetes mellitus and a high risk of cardiovascular disease in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial is currently unknown. An antiatherosclerotic effect is considered unlikely given the speed of the observed decrease in cardiovascular mortality. Hemodynamic effects, such as reductions in blood pressure and intravascular volume, and involving osmotic diuresis, may provide a more plausible explanation. Metabolic effects, such as cardiac fuel energetics, and hormonal effects, such as increased glucagon release, may also contribute to the results observed during EMPA-REG OUTCOME. This review discusses the main hypotheses suggested to date.
Document type :
Journal articles
Complete list of metadata

Cited literature [90 references]  Display  Hide  Download
Contributor : Marie-Hélène Derudas Connect in order to contact the contributor
Submitted on : Tuesday, June 6, 2017 - 3:50:55 PM
Last modification on : Wednesday, March 23, 2022 - 3:51:03 PM


Publication funded by an institution




Bart Staels. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. The American Journal of Medicine, Elsevier [Commercial Publisher] 2017, 130 (6S), pp.S30-S39. ⟨10.1016/j.amjmed.2017.04.009⟩. ⟨inserm-01533572⟩



Record views


Files downloads